Behrens, F., Tak, P. P., Østergaard, M., Stoilov, R., Wiland, P., Huizinga, T. W., . . . Burkhardt, H. (2015). MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: Results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).
Chicago-Zitierstil (17. Ausg.)Behrens, Frank, et al. MOR103, a Human Monoclonal Antibody to Granulocyte–macrophage Colony-stimulating Factor, in the Treatment of Patients with Moderate Rheumatoid Arthritis: Results of a Phase Ib/IIa Randomised, Double-blind, Placebo-controlled, Dose-escalation Trial. Erlangen: Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2015.
MLA-Zitierstil (9. Ausg.)Behrens, Frank, et al. MOR103, a Human Monoclonal Antibody to Granulocyte–macrophage Colony-stimulating Factor, in the Treatment of Patients with Moderate Rheumatoid Arthritis: Results of a Phase Ib/IIa Randomised, Double-blind, Placebo-controlled, Dose-escalation Trial. Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2015.